This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.
Patients between 18 and 80 years old, with no gender restrictions.
Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI).
Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period.
Expected survival time<12 months;
Severe liver dysfunction (non heart disease induced ALT or AST>3x ULN) and cirrhosis;
Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period;
The researchers determined that other reasons were not suitable for participants in this experiment.